​

Humacyte (HUMA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HUMA Stock Forecast

Humacyte (HUMA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $4.75, with a high of $6.00 and a low of $3.50. This represents a 177.78% increase from the last price of $1.71.

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 High: $6 Avg: $4.75 Low: $3.5 Last Closed Price: $1.71

HUMA Stock Rating

Humacyte stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

HUMA Price Target Upside V Benchmarks

TypeNameUpside
StockHumacyte177.78%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts122
Avg Price Target$6.00$4.75$4.75
Last Closing Price$1.71$1.71$1.71
Upside/Downside250.88%177.78%177.78%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25241--7
Sep, 25241--7
Aug, 25141--6
Jul, 25151--7
Jun, 25151--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 13, 2025UBS$6.00$1.68257.14%250.88%
Aug 27, 2025Matt MiksicBarclays$3.50$1.47138.10%104.68%
Oct 18, 2024Matt O'BrienPiper Sandler$6.00$4.8623.46%250.88%
Oct 18, 2024Ryan ZimmermanBTIG$10.00$4.86105.76%484.80%
Dec 20, 2022Cowen CowenCowen & Co.$5.00$2.21126.24%192.40%
May 15, 2022Matt O'BrienPiper Sandler$4.00$5.37-25.51%133.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 27, 2025BarclaysOverweightinitialise
Nov 05, 2024H.C. WainwrightBuyBuyhold
Oct 18, 2024Cowen & Co.BuyBuyhold
Oct 18, 2024Piper SandlerNeutralNeutralhold
Oct 18, 2024BTIGBuyBuyhold
Sep 09, 2024EF HuttonBuyinitialise
Sep 05, 2024BenchmarkBuyBuyhold
Aug 27, 2024Cowen & Co.BuyBuyhold
Jun 17, 2024Cowen & Co.BuyBuyhold
Aug 14, 2023Piper SandlerNeutralupgrade

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.94$0.62$-1.07$-1.26----
Avg Forecast$-1.55$-0.41$-1.05$-1.35$-0.86$-0.21$0.54$1.68
High Forecast$-0.80$-0.08$-1.04$-1.05$-0.80$1.20$2.98$3.33
Low Forecast$-3.37$-0.92$-1.07$-1.49$-0.99$-0.76$-0.43$0.41
Surprise %-160.65%-251.22%1.90%-6.67%----

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.26M$1.56M------
Avg Forecast$1.22M$1.77M$50.00K$214.29K$9.53M$118.34M$270.38M$503.61M
High Forecast$2.34M$3.46M$87.74K$376.03K$14.17M$118.34M$270.38M$883.73M
Low Forecast$766.74K$666.66K$21.01K$90.04K$4.88M$118.34M$270.38M$211.62M
Surprise %3.16%-11.47%------

Net Income Forecast

$-350M $-210M $-70M $70M $210M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$37.54M$64.22M$-110.78M-----
Avg Forecast$-160.03M$-42.40M$-109.26M$-152.87M$-92.62M$-24.81M$120.10M$173.75M
High Forecast$-82.28M$-8.07M$-107.75M$-108.95M$-82.92M$124.10M$308.19M$344.23M
Low Forecast$-348.93M$-95.14M$-110.77M$-154.07M$-102.31M$-78.60M$-44.47M$42.79M
Surprise %-123.46%-251.48%1.39%-----

HUMA Forecast FAQ

Is Humacyte stock a buy?

Humacyte stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Humacyte is a favorable investment for most analysts.

What is Humacyte's price target?

Humacyte's price target, set by 10 Wall Street analysts, averages $4.75 over the next 12 months. The price target range spans from $3.5 at the low end to $6 at the high end, suggesting a potential 177.78% change from the previous closing price of $1.71.

How does Humacyte stock forecast compare to its benchmarks?

Humacyte's stock forecast shows a 177.78% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Humacyte over the past three months?

  • October 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Humacyte’s EPS forecast?

Humacyte's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.86, marking a -31.75% decrease from the reported $-1.26 in 2024. Estimates for the following years are $-0.21 in 2026, $0.54 in 2027, and $1.68 in 2028.

What is Humacyte’s revenue forecast?

Humacyte's average annual revenue forecast for its fiscal year ending in December 2025 is $9.53M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $118.34M, followed by $270.38M for 2027, and $503.61M for 2028.

What is Humacyte’s net income forecast?

Humacyte's net income forecast for the fiscal year ending in December 2025 stands at $-92.616M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-24.806M in 2026, $120.1M in 2027, and $173.75M in 2028.